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Severity and management of psoriasis
within primary care
Alan G. Wade1*, Gordon M. Crawford1, David Young2, Joyce Leman3 and Neil Pumford4
Abstract
Background: Scottish Intercollegiate Guidelines Network and National Institute of Health and Care Excellence
guidelines stress the importance of assessing patients with psoriasis for psoriatic arthritis, comorbidities associated
with severe disease and quality of life (QoL).
The purpose of the study was to evaluate the primary care management of psoriasis in relation to disease severity
and QoL from a patient’s perspective.
Methods: A cross-sectional survey of adults (≥18 years) with psoriasis managed in primary care was conducted in
Scotland over 1-year (2012–2013). Patients with psoriasis were identified and invited to participate in the online/
telephone survey. The questionnaires included; Dermatology Life Quality Index (DLQI), Self-Administered Psoriasis
Area and Severity Index (SAPASI), Psoriasis Epidemiology Screening Tool (PEST). The primary outcome measure was
DLQI. Secondary outcomes included; demographics; comorbidities; involvement of different body sites; SAPASI and
PEST scores. Relationships between measures were analysed using univariate analysis.
Results: The mean age of patients (n = 905) was 54.5 years (SD = 16.1), 436 (48.2 %) were men, and median DLQI
and SAPASI scores were 4.0 and 6.0, respectively. Current psoriasis treatments were topical only (587, 64.9 %), oral
medications or phototherapy (122, 13.5 %), biologics (26, 3 %) and none (156, 17.2 %). Despite SIGN
recommendations, 256 of 391 patients (65.5 %) with a DLQI >5 (at least a moderate effect on QoL) had not seen a
specialist during the past year. According to PEST scores, 259 patients (28.6 %) had symptoms suggestive of
psoriatic arthritis requiring rheumatology referral.
Conclusion: National recommendations are not being fully implemented in primary care in patients with psoriasis
or psoriatic arthritis.
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Background
Psoriasis is a common, chronic inflammatory skin disease,
which affects 1 to 2 % of the population in the United
Kingdom (UK). The disease can vary widely in severity;
many people with psoriasis have an impaired quality of life
(QoL) due to the significant impact of the disease on func-
tional, psychological, and social well-being.
Several different body sites can be affected, including
areas that are difficult to conceal, such as the face, scalp,
and nails. The presence of visible lesions can have a
particularly marked impact on a patient’s QoL [1]. In the
UK, the patient-reported Dermatology Life Quality Index
(DLQI) is the most commonly used measure of QoL in
patients with psoriasis [2]. It is a simple, validated tool
consisting of 10 questions, is easy to use in primary care,
and allows measurement of limited disease, which may be
associated with significant psychosocial impact.
The importance of assessing all patients with psoriasis
for psoriatic arthritis and comorbidities associated with
severe disease, such as diabetes mellitus, dyslipidaemia,
hypertension, coronary heart disease, and depression, is
stressed in both the Scottish Intercollegiate Guidelines
Network (SIGN) and the National Institute for Health
and Care Excellence (NICE) guidelines [3, 4]. Obesity
and lifestyle factors, such as smoking and excessive
alcohol intake, may also be associated with psoriasis and
could affect other comorbidities [5].
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As the present survey was conducted in the West of
Scotland, the SIGN guidelines for the management of
psoriasis within primary care are relevant to this patient
population. These guidelines recommend that patients
with psoriasis have annual visits for DLQI score assess-
ment and screening for articular symptoms and comor-
bidities. They also advise that patients with suspected
psoriatic arthritis should be referred to a rheumatologist
for assessment.
The primary objective of this study was to evaluate the
distribution of DLQI scores amongst patients with psoria-
sis within primary care, thus providing a cross-sectional
insight into the impact of the disease, and to correlate
disease impact with the management of psoriasis.
Secondary objectives were to compare the patient Self-
Administered Psoriasis Area and Severity Index (SAPASI)
with treatments, comorbidities, and DLQI scores, and to
evaluate the prevalence of comorbidities and the involve-
ment of scalp, nails, palms or soles, and joints.
Methods
Selection and description of participants
Patients in a primary care setting were recruited for this
survey. General practitioners (GPs) within the West of
Scotland were contacted and all practices willing to
participate were included. At each practice, all adult pa-
tients (aged ≥18 years) with psoriasis were identified using
patient codes for psoriasis. Patients with other unspecified
skin conditions and/or receiving specified therapies for
psoriasis (e.g., tar products and systemic therapies such as
methotrexate and acitretin) were also identified and were
eligible for study inclusion if a diagnosis of psoriasis was
validated by their GP. All eligible patients were invited to
participate. Informed consent was obtained from partici-
pants for completion of the survey online or by telephone
and for their medical records to be evaluated for
additional information. No selection criteria were applied
at the stage of practice or patient selection that could
introduce bias. The National Research Ethics Centre con-
firmed that formal ethical approval was not required.
Data collection
Patient survey
The study was conducted over a 1-year period between
December 2012 and December 2013. The survey collected
demographic details and information on comorbidities,
alcohol and smoking intake, disability living allowance
(DLA) and/or work status, and the involvement of differ-
ent sites such as nails, scalp, and joints. The DLQI was the
main assessment tool used in this study. However, the
SAPASI, a patient-assessed version of the widely used
Psoriasis Area and Severity Index (PASI) designed to
measure the severity of psoriasis, and the Psoriasis
Epidemiology Screening Tool (PEST), designed to screen
for psoriatic arthritis, were also included [6, 7]. Patients
completed the questionnaire online or used a free-of-
charge telephone line and were led through the same
questionnaire by a nurse who had been trained on clinical
trials, the disease area, and the specific project.
Sample size and statistical methods
As the project was exploratory, no formal sample size
calculations were conducted. Patient characteristics, DLQI
and SAPASI scores, and responses were summarised
descriptively. Data were summarised as the number of
individuals for whom data were available and the number
with missing data for each variable. Associations between
outcomes (such as DLQI and affected site) were deter-
mined using univariate analysis (chi-square tests for trend).
The Mann–Whitney test was used to compare quantitative
variables between groups and the Pearson correlation coef-
ficient was used to quantify relationships between variables.
Statistical analyses were performed using Minitab, version
16 (Pennsylvania State University, PA, USA) on the full
analysis set, with no imputation of missing data.
Results
Twenty-seven practices in the West of Scotland agreed
to participate in the study. A total of 990 patients began
the survey; 905 (91.5 %) completed it. GP reports were
obtained for 688 of these patients (76.0 %).
Demographic data
The mean age of participating patients was 54.5 years;
similar numbers of men and women participated in the
survey (Table 1). The majority of patients (743; 82.1 %)
reported that they were receiving no treatment (n = 156)
or topical treatment only (n = 587) for psoriasis (Table 1).
Impact of disease (DLQI)
Patient DLQI scores are shown in Fig. 1. Psoriasis had
only a small or no effect on QoL (DLQI ≤5) in more
than half of the patients (514; 56.8 %). However, for 391
patients (43.2 %), the condition had at least a moderate
effect on QoL (DLQI >5; Table 1).
Of the 391 patients with a DLQI >5, 135 (34.5 %) had
seen a specialist in the past year and 256 (65.5 %) had not
been seen in secondary care. Although 156 patients were
receiving no treatment for their psoriasis, 28 (17.9 %) had
psoriasis that was affecting their lives to at least a moderate
effect (DLQI >5), indicating an unmet need for treatment.
Involvement of different sites, such as nails, scalp,
palms, and soles, are presented in Table 1. In univariate
analyses, there were significant associations between
DLQI category (0-5, 6-10, and 11-30) and affected site for
face, scalp, trunk, limbs, genitals, hands, feet, and nails.
Patients with psoriasis present at these sites were more
likely to be in a higher DLQI category. For example, 51.2,
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78.1, and 62.2 % of those in DLQI categories 0-5, 6-10, and
11-30 had scalp involvement compared with 48.9, 21.9, and
24.5 % with no scalp involvement for the respective cat-
egories (chi-square for trend = 54.513; P < 0.001). However,
the results are difficult to interpret, as patients generally
have disease involvement at multiple sites.
Severity of disease (SAPASI)
The SAPASI scores are shown in Fig. 2. There was a
significant correlation between patient-reported DLQI
and SAPASI scores (r = 0.580; P < 0.001), although there
was considerable variability (Fig. 3).
PEST questionnaire
On the PEST questionnaire, 259 respondents (28.6 %) had
a total of ≥3 positive responses, which signified possible
psoriatic arthritis, and indicated that a referral to a
rheumatologist was required. Both patient-reported and
GP medical record data noted that a smaller proportion of
patients had been diagnosed with psoriatic arthritis than
indicated from the PEST scale results. Ninety-six (11.9 %)
of the 809 patients with data self-reported that they had
received a diagnosis of psoriatic arthritis and 70 (13.8 %)
of the 506 patients with GP medical record data had a
diagnosis of psoriatic arthritis reported by the GP.
We report both the results of the GP survey and also that
of a more intensive scrutiny of GP notes, where the diagno-
sis of psoriatic arthritis was reported by the patient, but not
in the initial GP survey. There was no agreement between
Table 1 Demographic and Disease Characteristics, Patient Survey
Data
Characteristic (n = 905)
Sex, n (%)
Male/female 436/469 (48.2/51.8)
Age
Mean (SD) 54.53 (16.07)
Patient care, n (%)
Primary care only (general practitioner) 688 (76.0)
Specialista 217 (24.0)
DLQI
Mean (SD) 6.143 (6.198)
Median 4.0
Range 0–29
DLQI category: effect on patient’s life, n (%)
No effect (0–1) 249 (27.5)
Small effect (2–5) 265 (29.3)
Moderate effect (6–10) 204 (22.5)
Very large effect (11–20) 150 (16.6)
Extremely large effect (21–30) 37 (4.1)
SAPASI
Mean (SD) 6.369 (5.612)
Median 6.00
Range 0–59.76
Areas involved, n (%)
Limbs 669 (73.9)
Scalp 563 (62.2)
Trunk 432 (47.7)
Hands 324 (35.8)
Feet 247 (27.3)
Face 247 (27.3)
Nails 288 (31.8)
Genital area 167 (18.5)
Plaques on palms of hands 112 (12.4)
Plaques on soles of feet 101 (11.2)
Current treatments for psoriasis, n (%)
No treatment 156 (17.2)
Topical treatment onlyb 587 (64.9)
Oral drugs 68 (7.5)
Methotrexate 31 (3.4)
Phototherapy 54 (6.0)
Biologics 26 (2.9)
Other treatments (non-prescribed) 29 (3.2)
Missing 14 (1.5)
Table 1 Demographic and Disease Characteristics, Patient Survey
Data (Continued)
Presence of comorbidities, n (%)
Cardiovascular disease
(such as angina, heart problems,
high blood pressure)
247 (27.3)
High cholesterol 158 (17.5)
Depression/anxiety problems 152 (16.8)
Chest/respiratory problems
(eg, asthma, bronchitis, COPD)
111 (12.3)
Diabetes 81 (9.0)
Obesityc 77 (8.5)
Cerebrovascular disease
(such as stroke, haemorrhage, aneurysm)
28 (3.1)
Cancer (excluding skin cancer) 25 (2.8)
Liver disease 9 (1.0)
DLQI Dermatology Life Quality Index, SAPASI Self-Administered Psoriasis Area
and Severity Index, SD standard deviation, COPD chronic obstructive
pulmonary disease
aIncludes patients seen by a dermatologist, dermatologic nurse, and those
receiving oral or injection therapy
bA total of 707 patients received topical treatment; 120 patients received
topical and other treatment
cWeight and height data were not collected; thus, self-reported obesity could
not be verified and is likely to have been underreported by participants
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patients and GPs in the reporting of diagnoses of psoriatic
arthritis (κ =−0.276). The poor correlation between the
patient and GP reports of the diagnosis of psoriatic arthritis
was surprising and led to further investigation.
The data of 96 patients who had reported a diagnosis
of psoriatic arthritis that was not confirmed in the ori-
ginal GP survey were stringently reviewed (Table 2).
Of the 96 records, 83 could be reviewed; 60 of these
patients (72 %) had a record of a diagnosis of psoriatic
arthritis that had not been reported by the GP in the ori-
ginal survey. When the patient reported that the diagnosis
had been by a hospital specialist, this appeared to have a
much closer correlation with the diagnosis being recorded
in the notes (96 % of patients reporting a rheumatologist
and 73 % of patients reporting a dermatologist made the
original diagnosis). All but two records where the patient
reported the diagnosis having been made by a rheuma-
tologist in fact contained the information. For other
sources of diagnosis, the record appeared less robust
(36 % of GPs and 20 % other).
Seventy-two percent of the records reviewed more
rigorously had evidence that the diagnosis was correctly
reported by the patient, indicating that it was not easily
accessible or determined by the GPs originally complet-
ing the survey.
There still remains a potential issue in the identification
of psoriatic arthritis; 109 patients with a PEST scale score
≥3 did not have a recorded diagnosis of psoriatic arthritis,
Fig. 1 DLQI Scores, Patient Survey Data. DLQI Dermatology Life Quality Index
Fig. 2 SAPASI Scores, Patient Survey Data. SAPASI Self-Administered Psoriasis Area and Severity Index
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which may be due to the absence of a referral to a rheuma-
tologist and a lack of a definitive diagnosis rather than a re-
cording in the GP records of “arthritis or joint pains”.
Presence of comorbidities
Cardiovascular disease was the most commonly reported
comorbidity (Table 1). In univariate analyses, the diagnosis
of depression/anxiety as a comorbidity was associated with
a higher DLQI than expected (chi-square for trend = 13.307;
P <0.001).
Lifestyle factors
Lifestyle factors (alcohol/smoking) and the number of
patients on DLA and having time off work because of
psoriasis are shown in Table 3. Thirty-seven patients (8 %
of those working) reported having taken some time off
work because of their disease in the previous 30 days and
had significantly higher median DLQI scores than those
who had not taken any time off (12 vs 5, Mann–Whitney
test; P < 0.001).
Discussion
In all conditions, the importance of obtaining patients’
views to assess the impact of the disease is becoming in-
creasingly recognised. However, there is little published
information about the treatment, management, and im-
pact of psoriasis on patients in the United Kingdom
from the patients’ perspective.
This survey was designed primarily to gain more insight
on the impact of psoriasis on patients in primary care in
the UK (using a patient cohort from the West of Scotland)
by evaluating DLQI scores. The DLQI is the most widely
used tool to measure the QoL impact of psoriasis. Al-
though clinicians may undertake an “objective” assess-
ment of disease severity, the significant psychosocial
impact associated with limited disease may go unrecog-
nised without the use of the DLQI (or similar instru-
ments) to measure the impact of psoriasis on a patient’s
QoL. The SIGN guidelines emphasise the importance of
using the DLQI in primary care to assess the impact of
the condition and to guide appropriate specialist referral.
The correlation of DLQI with PASI/SAPASI in pa-
tients with psoriasis is not always simple; a previous
study investigating the relationship between SAPASI and
DLQI found a poor correlation between the two mea-
sures [8] And although our data showed a reasonable
correlation, there was considerable variability (Fig. 3).
Limited disease at difficult, sensitive sites such as nails
and genitals may lead to an imbalance between disease
severity assessed by PASI/SAPASI and the impact of the
disease assessed by the DLQI. Hence, we have focussed
on using the DLQI to assess the impact of the condition
in our analyses.
Fig. 3 Relationship Between DLQI and SAPASI Scores, Patient Survey Data. DLQI Dermatology Life Quality Index, SAPASI Self-Administered Psoriasis
Area and Severity Index
Table 2 Patient-Reported Psoriatic Arthritis: HCP Reported as
Having Made Diagnosis and Percentage Recorded in GP Survey
HCP n Notes reviewed Positive record
in GP notes
No record
in GP notes
GP 24 22 8 (36 %) 14 (64 %)
Dermatologist 12 11 8 (73 %) 3 (27 %)
Rheumatologist 55 45 43 (96 %) 2 (4 %)
Other 5 5 1 (20 %) 4 (80 %)
Total 96 83 60 (72 %) 23 (28 %)
GP general practitioner, HCP healthcare provider
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The SIGN guidelines recommend referral to a specialist
for patients with psoriasis treated by a GP who do not
respond to topical therapy and have a DLQI >5. In this
cross-sectional survey, 65.5 % of those with a DLQI >5 had
not seen a specialist during the past year, suggesting that a
significant proportion of patients are not being referred to
specialists despite SIGN guideline recommendations.
This study also highlighted an unmet need for more ef-
fective treatment, as a significant proportion of respondents
had a DLQI >10, indicating that psoriasis had a very large
or extremely large effect on their lives, were receiving no
treatment (7 %), or only topical treatment (22 %). A recent,
self-administered postal questionnaire conducted with 1564
members of the Psoriasis Association also showed that
patients with psoriasis generally were dissatisfied with their
current treatment [9].
Our survey population was comparable to the general
population regarding the number of patients who smoked
and had depression/anxiety; 23.4 % of our survey popula-
tion reported being smokers compared with 20 % for
those aged older than 16 in the UK and 16.8 % reported
depression/anxiety compared with 17.2 % of those aged
older than 16 having some evidence of depression/anxiety
in Scotland [10, 11]. However, other comorbidities associ-
ated with severe disease, such as cardiovascular disorders,
were reported more commonly in our population than in
the general population (27.3 vs 10.1 % of the population
older than 16 years with a long-standing condition of the
heart and circulatory system according to the Office of
National Statistics) [12].
The PEST questionnaire revealed that although 29 % of
patients self-reported symptoms suggestive of psoriatic
arthritis (indicating the need for referral to a rheumatolo-
gist), a considerably smaller proportion reported a diagnosis
of the condition or had had it recorded in their medical
records. There was good agreement between patient report-
ing and GP medical records (after secondary review of the
GP records) relating to the diagnosis of psoriatic arthritis,
suggesting that patient recollection of the diagnosis was
excellent. It is also of some concern that the initial reports
obtained from the GP survey were incomplete. GPs
generally seemed to underrecord psoriatic arthritis. It is a
condition that often goes undiagnosed in primary care,
possibly due to factors such as lack of awareness, time
constraints, or symptoms attributed to an alternative diag-
nosis. Of those reported with the condition by a GP, most
correlated with patient-reported PEST, although some did
not, possibly due to confusion with other types of arthritis.
Although psoriasis affects as much as 2 % of the UK
population, most of whom are managed in primary care,
there is little detailed information in the literature regarding
psoriasis management in this setting from a GP and patient
perspective [13]. The fact that many patients feel that their
GP lacks specialist knowledge of the condition and the
available treatments suggests a need for improved GP
training, and for an increase in the number of dermatology
specialist nurses in primary care settings. Qualitative
studies, such as that conducted by Nelson and co-workers,
have highlighted the need for GPs to improve their skills in
the management of psoriasis and for long-term initiatives
in partnership with patients that focus on improving QoL
[9, 13]. The combination of qualitative and individual case
analysis with quantitative assessments of QoL could make a
valuable impact on future research into psoriasis and the
development of suitable treatments [14].
Table 3 Smoking, Alcohol Intake, Employment Status, Time Off
Work Because of Psoriasis, and DLQI Scores, Patient Survey Data
N (%) of patients
(n = 905)
Smoking status, n (%)
Smoker 212 (23.4)
Non-smoker 385 (42.5)
Ex-smoker 308 (34.0)
Alcohol weekly intake (units)
Mean (SD) 7.2 (12.3)
Median 3.0
Range 0–200
Employment/education status, n (%)
No – not currently employed or in education 445 (49.2)
Yes – currently employed or in education 460 (50.8)
Receiving Disability Living Allowance
No 774 (85.5)
Yes 120 (13.3)
Prefer not to answer 11 (1.2)
Time off work in past 30 days
(n, % of those in work)
No 423 (92.0)
Yes 37 (8.0)
< 1 day 11 (2.4)
1 day 7 (1.5)
2–3 days 10 (2.2)
4–5 days 4 (0.9)
> 5 days 5 (1.1)
DLQI score for no time off work (n = 423)
Mean (SD) 6.4 (5.9)
Median 5.0
Range 0–26
DLQI score for time off work (n = 37)
Mean (SD) 11.8 (7.8)
Median 12.0
Range 0–26
DLQI Dermatology Life Quality Index, SD, standard deviation
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Our study has several limitations, including its cross-
sectional methodology. Medical history was self-reported
and may be subject to recall bias. Although there was no se-
lection bias in the practices approached to participate in the
study, there will have been some self-selection in practices
and patients willing to participate in the survey. Weight and
height data to verify self-reported obesity was lacking.
Strengths of the study include the large sample size
from patients in the primary care setting and a high
completion rate for all questions. Medical records were
reviewed for 76 % of the survey participants, which
allowed correlation of data collected from both sources.
Conclusions
This study showed that from a patient perspective, the
burden of illness from psoriasis was significant and that
patient reporting of the diagnosis of psoriatic arthritis
was accurate, particularly where a specialist was involved
in the diagnosis. There was evidence that SIGN guide-
line recommendations are not being fully implemented
in primary care for patients with psoriasis or psoriatic
arthritis, possibly due to time constraints or a lack of
awareness. Further studies are warranted to determine
the reasons for the lack of adherence to SIGN guidance
and to make recommendations for improving adherence.
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